Replies to post #6895 on The Rising Influence of Rising Affluence

[DewDiligence]

More on ABT’s prospects in emerging markets:

http://www.forbes.com/sites/brucejapsen/2013/04/17/new-abbott-fills-chinas-craving-for-baby-formula-nutrition

[DewDiligence]

Profile of ABT’s competition in the bioabsorbable stent market:

http://seekingalpha.com/article/1497092-abbott-labs-absorb-and-the-dissolvable-stent-race

ABT’s ABSORB product is approved for marketing in 30 countries, but is still in phase-3 in the US (#msg-83166556). As the above article notes, ABT prefers to call its ABSORB product a scaffold rather than a stent, as the latter term suggests permanence.